A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

Inclusion Criteria: * Body mass index ≥ 30 kg/m2 * Waist circumference ≤ 57 inches * Fasting Plasma Glucose \< 7 mmol/L (126 mg/dL) * HbA1c \< 6.5% * Controlled Attenuation Parameter ≥ 300 dB/m by FibroScan * Liver fat by MRI-PDFF ≥ 10%. Exclusion Criteria: * A history of or active chronic liver disease due to alcohol, auto-immune, HIV, HBV or active HCV-infection or NASH disease * Any history of clinically significant chronic liver disease including esophageal varices, ascites, encephalopathy or any hospitalization for treatment of chronic liver disease; or Model for End Stage Liver Disease (MELD) ≥ 10 * Previous surgical treatment for obesity * Uncontrolled hypertension * Any weight control treatment * History or current diagnosis of acute or chronic pancreatitis or factors for pancreatitis * History of major depression, anxiety, suicidal behavior or attempts, or other psychiatric disorder requiring medical treatment * History or current diagnosis of heart disease * Presence of clinically significant ECG findings * History of renal disease or abnormal kidney function tests * History of alcohol or illicit drug abuse * Daily heavy use of cigarettes or any tobacco product